today announced that the first patient has been dosed in its Phase 1b clinical In preclinical models of cornea endothelial dystrophies, a Surrozen antibody-based Wnt mimetic reduced corneal edema ...

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic ...

(Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 ...

The FDA did not agree with a supplemental Biologics License Application for the addition of extended dosing intervals of up to 24 weeks across currently-approved indications.

That's really where we're at in the present day in terms of trying to address some of our more common muscular dystrophies. But there are many disorders for whom standard of care is still the best ...

Authors defined metabolic syndrome as “the set of factors that increase the risk of cardiovascular disease and diabetes, such as hypertension, central obesity, insulin resistance, and atherogenic ...

CAMBRIDGE, Mass., April 22, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial ...

In 2005, the MDCC collected and integrated the recommendations of muscular dystrophy researchers, physicians, patients, family members, and other stakeholders into the Action Plan for the Muscular ...

Dr. Mathews’ NIH-funded project with the Iowa Wellstone Center focuses on people with dystroglycanopathies—a collective term that refers to muscular dystrophies with abnormal glycosylation of ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2025 financial results after the ...